Advances in whole-genome and exome sequencing initiated our discoveries of the high frequency of mutations in spliceosome-associated genes, such as SRSF2, SF3B1, and U2AF, particularly, in hematologic malignancies, which has led us to revisit the field of RNA splicing and recognize its significant roles in cancer development and progression11,12. The gene discussed is SRSF2; the disease is hematologic disorder.